Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Kim N ChiSimon ChowdhuryAnders BjartellByung Ha ChungAndrea Juliana Pereira de Santana GomesRobert GivenAlvaro JuárezAxel S MerseburgerMustafa ÖzgüroğluHirotsugu UemuraDingwei YeSabine Brookman-MaySuneel D MundleSharon A McCarthyJulie S LarsenWeili SunKatherine B BevansKe ZhangNibedita BandyopadhyayArchana M AgarwalPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The final analysis of TITAN confirmed that, despite crossover, apalutamide plus ADT improved OS, delayed castration resistance, maintained health-related quality of life, and had a consistent safety profile in a broad population of patients with mCSPC.